A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This two-arm study will compare the efficacy and safety of erlotinib (Tarceva) versus placebo
in participants with resected head and neck squamous cell cancer who are receiving concurrent
chemoradiotherapy or radiotherapy alone. Participants will be randomized to receive either
erlotinib 150 milligrams (mg) orally (PO) once daily or placebo for 1 year until disease
progression or unacceptable toxicity.